Brand-name semaglutide, meaning Wegovy or Ozempic, straight from Novo Nordisk, is FDA-approved and now costs as little as $149 to $199 a month through the manufacturer’s own pharmacy. Compounded semaglutide vs. brand-name isn’t the easy-money question it was in 2023 anymore. The shortage that made compounding legal and cheap ended back in February 2025, and the FDA has spent the last year and a half tightening the rules around who can still sell you a compounded version. Some of it is still legal. A lot of it isn’t, and the companies that used to sell it have been dropping out one by one.
Here’s what’s actually true right now, priced straight from the source.
Quick verdict
Pick a brand name if you want something the FDA has actually reviewed, you have commercial insurance that might knock your price down to $25 a month, or you just don’t want to worry about which pharmacy is legit this month.
Pick compounded if: you have a documented reason a commercial product won’t work for you (like an allergy to an inactive ingredient), your doctor agrees, and you’ve confirmed the pharmacy is a real, state-licensed 503A operation. This is a narrow lane now, not a budget hack.
Current price snapshot: Wegovy through NovoCare Pharmacy starts at around $149 to $199 a month, depending on dose and format, with self-pay maxing out near $399 to $499 for the highest doses. That’s the number to compare everything else against.
What does “compounded” actually mean here?
A compounding pharmacy prepares a custom formulation of a drug rather than using the mass-produced, FDA-approved version. During the Wegovy and Ozempic shortage, this was legal on a large scale because federal law allows it when a drug is officially in short supply. Compounded semaglutide has the same active ingredient as Ozempic and Wegovy. It’s just not the finished, FDA-approved product, and it never went through the same testing and manufacturing checks.
Sounds like a fair trade for a lower price, right? Well, hold on. That trade only made legal sense while the shortage lasted.
The FDA ruled on compounded semaglutide in 2026
This is the part that actually changed everything, so let’s go through the timeline plainly.
February 2025: The FDA declared the semaglutide shortage over. That single decision removed the legal basis that allowed 503A pharmacies and 503B outsourcing facilities to compound semaglutide at scale. 503A pharmacies have until April 22, 2025, to wind down mass compounding, and larger 503B facilities have until May 22, 2025.
Late 2025 into 2026: The FDA started sending warning letters. A lot of them. Over 55 went out in September 2025 to online sellers of compounded GLP-1s; another large wave hit in March 2026, and 25 more went out in June 2026, mostly over misleading advertising that made compounded products sound FDA-approved when they aren’t.
April 30, 2026: The FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the list of ingredients that 503B outsourcing facilities are even allowed to use. If this becomes final, it closes the door on large-scale compounding of these drugs for good, even if there’s another shortage down the road. The public comment period closed June 29, 2026. As of this writing, it’s a proposal, not a final rule.
So what’s still allowed? A state-licensed 503A pharmacy can still compound semaglutide for one specific patient if a licensed prescriber documents a real clinical reason; the FDA-approved product won’t work for that person. An allergy to an inactive ingredient is an example the FDA itself has pointed to. What’s no longer allowed is a pharmacy mass-producing semaglutide as a cheaper copy of Ozempic or Wegovy and selling it to anyone who fills out an online form. That’s exactly what most of the warning letters have targeted.
One more thing worth knowing. The FDA has said it received more than 455 adverse event reports tied to compounded semaglutide, including dosing errors from patients drawing the wrong amount out of multidose vials, some serious enough to need hospital care. That’s part of why the agency’s posture has hardened so much. [link: Compounded Semaglutide Safety Guide]
Brand -semaglutide: what it actually costs right now
Here’s the thing that surprised me looking into this: brand-name semaglutide is not the $ 1,300-a-month drug it used to be, at least not if you go straight through the manufacturer.
NovoCare Pharmacy (Novo Nordisk, the maker of Ozempic and Wegovy): NovoCare lists it clearly on its own pricing page. Self-pay Wegovy pen runs $199 a month for the first two starter doses through the end of 2026, then $349 a month for standard doses and $399 a month for the highest dose. The Wegovy pill (oral semaglutide) is cheaper, listed at $149 a month for most doses. Ozempic follows a similar structure: $199 a month for starter doses for the first two fills, then $349 to $499 depending on dose. If you have commercial insurance, NovoCare’s savings card can bring your cost down to $25 a month. I’d genuinely recommend checking your eligibility here before looking anywhere else. [link: Wegovy Cost Guide]
Ro: Ro’s own site lists Wegovy at $199 a month for the first two months on starter doses, on top of a separate membership fee of $39 for month one, then $74 a month if you prepay annually or $149 a month if you pay monthly. Ro used to be one of the bigger sellers of compounded semaglutide. As of this writing, their public pricing table centers on branded Wegovy, not a compounded product, which lines up with the wider industry pullback described above.
Hims & Hers: This one changed a lot recently. Hims settled a patent lawsuit with Novo Nordisk in March 2026 after a short-lived, and honestly kind of wild, $49 compounded oral semaglutide pill launch got sued into oblivion. As part of that settlement, Hims agreed to sell branded Wegovy, Ozempic, and Zepbound instead and exited compounded semaglutide for new patients. Their site is clear about the membership cost: $39 for the first month and $149 a month after that. What it doesn’t show you up front is the medication price, which is a bit annoying, honestly, since it depends entirely on what you’re prescribed and isn’t revealed until you’re in the signup flow. Their own newsroom has advertised the Wegovy pill starting at $149 a month ,cash pay, so use that as a ballpark, not a locked number.
Where compounded semaglutide is still legally sold
Henry Meds: Henry Meds’ official treatment pages advertise pricing that “starts at $179 a month,” but that headline price is not clearly tied to the standard weekly injectable dose most people actually sign up for. You have to go through their intake quiz to see a locked-in number for your specific dose. I couldn’t get a confirmed, exact price for standard-dose injectable semaglutide straight from their public pages, so I won’t guess one here. Henry Meds does work through licensed US compounding pharmacies and hasn’t received an FDA warning letter as of the most recent check, which puts it in a cleaner standing than a lot of competitors.
If you’re going the compounded route anywhere, ask the company to name their compounding pharmacy and confirm it’s a state-licensed 503A operation. If they won’t tell you, that’s your answer.
Compounded vs brand name: side by side
| FDA approved | Yes | No |
| Legal status in 2026 | Fully legal, sold directly by manufacturer | Legal only with a documented patient specific need, per a state licensed 503A pharmacy |
| Starting price | $149 to $199 a month (self pay, starter dose) | Varies, often not disclosed until signup; some sites report $180 to $300 a month |
| Insurance path | Yes, savings card can bring cost to $25 a month | Rarely accepted |
| Manufacturing oversight | FDA reviewed and approved formulation | Not FDA reviewed, quality depends on the individual pharmacy |
Pick a brand name if you want the version the FDA has actually signed off on, or you have insurance that might make it cheaper than compounded anyway.
Pick compounded if your doctor has a documented reason the approved product won’t work for you specifically, and you’ve verified the pharmacy is properly licensed. Not because it’s cheaper. In a lot of cases now, it isn’t even cheaper.
FAQ
Is compounded semaglutide illegal now? Not entirely. Mass-produced, non-patient-specific compounded semaglutide is no longer permitted. A state-licensed 503A pharmacy can still compound it for an individual patient with a documented medical reason and a valid prescription.
Why did Hims stop selling compounded semaglutide? Novo Nordisk sued Hims over a compounded oral semaglutide pill in February 2026. The two companies settled in March 2026, and Hims agreed to sell Novo’s branded products instead of compounding.
Is brand-name Wegovy actually cheaper than compounded now? Sometimes, yes. NovoCare’s self-pay pricing starts around $149 to $199 a month, which is close to or below what several compounded providers charge once you add up medication and membership fees. Always compare the full monthly total, not just the headline number.
Will the FDA ban compounded semaglutide completely? Not yet. The FDA has proposed removing semaglutide from the list of 503B facilities that can use it, but as of this writing, that’s a proposal, not a final rule. 503A pharmacies can still compound it under narrow, patient-specific conditions regardless of how that proposal ends up.
Can I still get compounded semaglutide from a legitimate source? Yes, through a state-licensed 503A pharmacy with a valid, patient-specific prescription. Ask any provider to name their compounding pharmacy before you sign up.
My honest take
I went into this expecting compounded semaglutide to still be the obvious budget pick, and it just isn’t anymore, at least not automatically. Brand-name Wegovy through NovoCare is priced close enough to what compounded providers charge that the FDA approval and insurance eligibility make brand-name the easier default for most people. Compounded semaglutide still has a real, narrow place for patients with a documented medical reason to need it, but it’s not the wide-open discount lane it was during the shortage. Talk to your doctor about which option actually fits your situation. This article is informational, not a recommendation for what you personally should take.